uniQure N.V. (NASDAQ:QURE) stock has received a short term price target of $ 35.33 from 6 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $13.71. The higher estimate of target price is $60 , while the lower price target estimate is $23
For the current week, the company shares have a recommendation consensus of Buy.
uniQure N.V. (NASDAQ:QURE) stock ended Monday session in the red zone in a volatile trading. The stock closed down 1.9 points or 16.09% at $9.91 with 925,416 shares getting traded. Post opening the session at $11.77, the shares hit an intraday low of $9.7 and an intraday high of $12 and the price was in this range throughout the day. The company has a market cap of $246 million and the number of outstanding shares have been calculated to be 24,812,154 shares. The 52-week high of uniQure N.V. (NASDAQ:QURE) is $36.38 and the 52-week low is $10.61.
Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. The Companys first product is Glybera, for the treatment of lipoprotein lipase deficiency (LPLD). In the clinical pipeline, it has gene treatments for hemophilia, porphyria, Parkinson, Sanfilippo B syndrome and hearing loss. Additionally, it is engaged in the development of therapies based on adeno-associated virus (AAV) through multiple collaborations. The Company uses modular technology platform, including a cost effective manufacturing process. In August 2014, Uniqure NV acquired InoCard GmbH, an early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease.